Menu Back toIs There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?

DIA 2021 Global Annual Meeting


Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?

Session Chair(s)

Stephen  Keith, MD, MPH

Stephen Keith, MD, MPH

  • Senior Medical Director, Medical and Scientific Management, Clinical Solutions
  • Syneos Health, United States
With combined experience running studies and drafting FDA rules, this panel will show why guidance on trial diversity has not produced results. Audience polling will help illuminate how incentives can translate guidance into thoughtful action.
Learning Objective : Characterize obstacles that rendered FDA guidance on clinical trial diversity ineffective thus far; Identify federal initiatives, such as the Orphan Drug Act, that have successfully galvanized industry in other contexts; Define incentives that might invigorate industry-led minority enrollment programs; Evaluate an audience ranking of proposed incentives using real-time digital polling.

Speaker(s)

Peter J. Pitts

Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?

Peter J. Pitts

  • President
  • Center for Medicine in the Public Interest (CMPI), United States
David H Strauss, MD

Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?

David H Strauss, MD

  • Special Lecturer
  • Columbia University , United States
Kimberly Y. Smith, MD, MPH

Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?

Kimberly Y. Smith, MD, MPH

  • Senior Vice President, Head of Research and Development
  • ViiV Healthcare, United States